MSB trading, page-547

GVHD is small beer. Rheumatoid Arthritis, Heart Failure, Myocardial Function in LVAD Recipients and Chronic Discogenic Lumbar Back Pain are the Teir 1 indications IMHO. Rheumatoid Arthritis on the back burner waiting for a Phase 3 trial.

ClinicalTrials.gov:
Phase 3: Treatment of Heart Failure - NCT02032004
Recruiting, Last Update: October 31, 2016
- Estimated Primary Completion Date: February 2018
- Estimated Study Completion Date: February 2019

Phase 2: Myocardial Function in LVAD Recipients - NCT02362646
Active, not recruiting, Last Update: September 15, 2017
- Estimated Primary Completion Date: August 2018
- Estimated Study Completion Date: August 2019

Phase 3: Chronic Discogenic Lumbar Back Pain - NCT02412735
Recruiting, Last Update: February 26, 2018
- Estimated Primary Completion Date: October 2019
- Estimated Study Completion Date: October 2020

If we have a positive result for any of these, then my target for end of 2019 is $5.
Each additional positive result, add another $5.
Myocardial Function in LVAD Recipients doesn't need to get to Phase 3 success, rest do.
Success is not guaranteed with clinical trials. Even if the science is correct the trial has to be engineered correctly to show efficiency. Safety for these indications is already shown.